1 / 51

HIGH TECH 2012

HIGH TECH 2012. 25-26 et 27 janvier 2012 – Marseille - Palais des Congrès RAC et dysfonction VG Docteur Bertrand CORMIER. Cas clinique n°1 Mr DEL. André, 73 ans. HTA ancienne – Tabac modéré RA connu de longue date, jugé modéré Poussée récente d’insuffisance cardiaque Auscultation pauvre

sinclair
Télécharger la présentation

HIGH TECH 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIGH TECH 2012 25-26 et 27 janvier 2012 – Marseille - Palais des Congrès RAC et dysfonction VG Docteur Bertrand CORMIER

  2. Cas clinique n°1Mr DEL. André, 73 ans • HTA ancienne – Tabac modéré • RA connu de longue date, jugé modéré • Poussée récente d’insuffisance cardiaque • Auscultation pauvre • ECG : RS, QRS fins – Coro normale • Echo VG 58/47 SIV/PP = 10/10 FE 20 % VTi sous Ao = 8 cm – gradient moyen 15 – Sa0 =0.7 • Dobutamine = O réserve contractile • Dilatation aortique : O résultat fonctionnel

  3. Cas clinique n°1 • Scanner cardique:valve tricuspide calcifiée,anneau:23 • TAVI prothese Edwards 26

  4. cas clinique n°1 Suites simples; O SF Retour à domicile sous traitement medical Pronostic?(def à discuter)

  5. Cas Clinique n°2Mr ALV. Serge, 70 ans • Tabac sevré – DNID – 112 kg, 1m78 • CMD connue depuis 2006  coro : sténose D1 • Sclérose mitro-aortique - FEVG = 35 % • 2011 : 2 poussées d’IC globale • Echo FEVG = 35 % - gradient moyen 25 – Sao = 0.8 cm²

  6. Cas Clinique n°2Mr ALV. Serge, 70 ans – 2 • Echo Dobu RC +  gradient moyen = 45 • Scanner = valve tricuspide calcifiée – Sao = 0.9 cm² • RVA BP 23 – Suites simples, sortie à J+8

  7. EuroHeart Survey on VHDB.Iung Eur Heart J, 2003 • Prospective study in 92 centers from 25 countries = 5001 VHD • AS = 1197 pts  512 interventions : • EF ≥ 60 = 56.5 % 50-60 = 24.2 % 30-50 = 16.4 % < 30 = 2.9 %

  8. To operate or not pts with severe ASBT.Bouma, Heart 1999 • 205 pts prospectively evaluated; AVA < 1 cm², mean age= 78 yrs, 48% CAD • 94 pts : AVR 111: medical • 41 symptomatic pts no surgery : • LV dysfunction 14% • Advanced age 13% • Comorbidity 13% • Symptoms attributed to CAD 11% • Functional improvement 9% • Main risk factors:impaired LVF, NYHA Cl, age

  9. Why are so many pts with AS denied surgery ?B.Iung, Eur Heart J 2005 • EHS : 216 pts with severe symptomatic AS (angina or NYHA Cl III/IV) • AVR = 67 % medical= 33 % • Multivariate analysis • LVEF [OR = 2.27 for EF 30-50 % = 5.15 for EF ≤ 30 % • Age [OR = 1.84 for 80-85 yrs = 3.38 for ≥ 85 yrs vs 75-80 Associated with no surgery

  10. AS and LV systolic dysfunction • In the majority of pts with mild-moderate systolic dysfunction, decrease in SV and EF is related to reversible mismatch, likely to reverse when obstruction is relieved  pts with severe AS and EF < 50 % : Cl IC for AVR (ESC guidelines, 2008)

  11. AS and LV systolic dysfunction • Severe decrease in EF may be caused by decreased contractility associated with fibrosis due to hypertrophy or surimposed MI. Secondary improvement in LV function is uncertain. • The subgroup of pts with severely depressed EF and low flow raises diagnostic and therapeutic difficulties

  12. Flow dependence of AV resistance and LV stroke work loss • Valve resistance = 1.333 x P/Q dynes/s/cm-5 • LV SWL = 100 x P/ LVP (%) (Burwash, 1994)

  13. Calcific AS : time to look more closely at the valveCM OTTO, NEJM 2008

  14. Scanner MSCTThresholds

  15. Dobutamine Echocardiography in AS with LV dysfunction (EF< 0.35) and low gradient (P< 30 mm) • De Filippi (1995) • Severe AS :  VTI,  P, no change (<0.3 cm²) in AVA • Mild AS :  VTI,  AVA (> 0.3 cm²), no change in P • No reserve ? • Nishimura (2002) • Severe AS : P > 30 and AVA < 1.2 cm²

  16. Surgery of AS with LV dysfunction

  17. Low gradient AS : risk stratification by DSEJL Monin Circulation 2003 • Prospective multicenter study : 136 symptomatic pts, AVA = 0.7 cm² (0.6-0.8), MPG 29 mmHg (23-34), LVEF : 0.30 (0.24-0.35) – CI : 2.11 l/mn/m² (1.75-2.55) • Significant CAD = 46 % (MVD = 33 %) • Gr I : 92 pts with CR ( SV ≥ 20%) vs Gr 2 = 44 pts without CR • AVR in 70% of each Gr ;medical tt in pts with older age, comorbidities of pseudo severe AS (9/92 pts) • OM = 14 % (5% Gr I, vs 32 % Gr II, p < .002) • Predictors of OM : lack of CR (OR : 10.9, p< .001) and MPG ≤ 20 mmHg (OR : 4.7, p<.04) • Predictors of LT survival : AVR (p=.001) and CR (p.001)

  18. Indications for AVR in AS with LV dysfunction • ACC/AHA  no recommendation • ESC : AS with low MPG (< 40 mmHg), LV dysfunction and contractile reserve : Cl II a C and no contractile reserve: Cl II b C • Decision making according to clinical condition, valve calcification, extent of CAD

  19. Outcome after AVR for LF/LG AS without CRC. Tribouilloy, JACC 2009 • 81 pts prospectively included – AVA < 1 cm², EF ≤ 40 %, MPG ≤ 40 mmHg; no contractile reserve • 55 pts : AVR – 26 :medical; Mean Fu : 37 ± 41 m • Operative mortality : 22%, 5 yrs survival (excluding OM) : 69 ± 8%

  20. Therapeutic decision in patients without CR • BAV as a diagnostic test • AVR considered in pts with calcified valve, low comorbidity, with MPG > 20 mmHg and without large scar of infarction

  21. Comparison of hemodynamic performance of percutaneous and surgical BP in ASMA Clavel, JACC 2009 50 PAVI (femoral : 38 ; apical 12)matched with 50 CE Magna (ST gr) or freestyle (SL gr) for sex, aortic annulus diameter, LVEF, BSA and BMI

  22. Long-term outcomes after TAVI in high-risk ptsThe UK registry – NE MOAT JACC 2011 ; 58 : 2130-8 • All TAVI prospectively collected (2007-2009) within the UK (25 centers), mortality status in 100% by December 2010 • 870 pts = TF route : 599 (69 %) other 271 (31 %) Medtronic Corevalve = 452 (52 %) Edwards Sapien = 410 (48 %) • 213 pts alive at 2 years FU

  23. NE Moat JACC 2011

  24. NE Moat JACC 2011

  25. AS and poor LV functionConclusion - 1 • LV dysfunction is an uncommon consequence of AS (< 10 %) • MPG > 30 mmHg despite low EF in favor of mismatch and represents an indication for AVR

  26. Conclusion - 2 • The subgroup of pts with severe LV dysfunction, LF, LMPG poses diagnostic and therapeutic difficulties : due to the flow dependence of the main hemodynamic criteria, the diagnosis of severe AS is based on anatomy and the response to Dobutamine infusion • Patients with CR should undergo valve intervention as well as patients without CR but with low comorbidity, MPG > 20 mmHg and no extensive scar of MI

More Related